Echo Therapeutics Inc fka ECTE

[xxxxtrader]

ECTE $3.32/$3.35 FDA predikted within 2 weakz, Road Show nexxxxt Tuesday... 3.5 nn belo iz tha

/// L-O-A-D-I-N-G Z-O-N-E ///

Window of Opportunity iz this afternoon nn tomorrow

Now Loading bakk in 1/4 positshun in Low 3z "sweet spot"

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=59768384

Targit remainz $5 on FDA approval

Echo Therapeutics to Present at the ROTH 23rd Annual Growth Stock Conference
4 hours 32 minutes ago - PR Newswire Europe via Comtex
PR Newswire EuropeEcho Therapeutics, Inc. , a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude(TM) SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the ROTH 23(rd) Annual Growth Stock Conference.

Dr. Mooney will make a corporate presentation to prospective corporate partners and investors on Tuesday, March 15th at 3:30PM PST. The Company's presentation will be delivered at the Ritz Carlton Laguna Niguel in Dana Point, California.

About Echo Therapeutics

Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

For More Information: Patrick T. Mooney, M.D. Media: Richard Stern Chairman and Chief Executive Officer Stern & Co. [phone] [phone]

CONTACT: Patrick T. Mooney, M.D., Chairman and Chief Executive Officer,Echo Therapeutics, Inc., [phone]; or Media: Richard Stern, Stern &Co., [phone]